Podcasts about Molecular oncology

February is ovarian cancer awareness month. Dr Olga Kondrashova leads the Molecular Oncology team at the Queensland Institute for Medical Research, QIMR Berghofer. She told SBS Russian about the changes in the ovarian cancer treatments, and about her journey in science. - Февраль - это месяц повышения осведомленности о раке яичников. Доктор Ольга Кондрашова возглавляет группу молекулярной онкологии в Институте медицинских исследований Квинсленда, QIMR Berghofer. Она рассказала о том, как изменился подход к лечению рака яичников, почему его сложно диагностировать, а также о своем пути в науку.

Does becoming an editor mean you are leaving research? Can you ever go back to academia? And why should you "follow the cookies"? Join us as we chat with seasoned professionals who have transitioned from the lab bench to the editorial desks at Molecular Oncology, Nature Reviews and Cell. They share their personal journeys, highlight the skills necessary for this unique career path, and offer advice for researchers considering a shift into scientific publishing. Access transcripts for all our episodes at magazine.eacr.org/podcast.

In this episode we're joined by editors from Cell, Nature Reviews and Molecular Oncology to discuss the process of scientific publishing: from the steps involved, including the peer review stage, to choosing the best home for your research; from preprints to peer-reviewed journals; from APCs and how to get a discount to the importance of engaging in an open conversation about your research with editors even prior to your paper submission.

Send us a Text Message.Joseph Ferra is CEO of Elevation Oncology ( https://elevationoncology.com/ ), a clinical stage biopharmaceutical company focused on the development of precision oncology products, specifically antibody-drug-conjugates (ADCs), for patients with genomically defined cancers, where he brings over 20 years of financial, strategic and leadership experience in the pharmaceutical/biotechnology industry. Prior to becoming CEO, he served Elevation as Chief Financial Officer and Interim CEO. Before joining Elevation, Joseph was Chief Financial Officer of Syros Pharmaceuticals where he led the development and implementation of key financial and capital strategies and contributed to corporate initiatives. Previously, he spent over a decade as an investment banker in the biotechnology and pharmaceutical industry, where he established a strong track record of advising on equity and M&A transactions. This included serving as Managing Director and Co-Head of Healthcare Investment Banking at JMP Securities and being a member of the investment banking groups at JP Morgan and UBS. Earlier in his career, Joe served in sales and engineering roles in the life science tools industry. He earned his MBA from The Stephen M. Ross School of Business at the University of Michigan. He obtained a B.S. in Chemistry with Distinction from Purdue University, where he contributed to published papers and conducted research at the National Institutes of Health. Dr. David Dornan is Chief Scientific Officer of Elevation Oncology where he brings over two decades of industry and academic oncology drug discovery and development experience. His research spans across multiple therapeutic modalities targeting cancer susceptibilities and modulating the immune system to translate into meaningful therapeutic interventions for patients. He joins Elevation Oncology from Bolt Biotherapeutics. As Chief Scientific Officer, he was responsible for the scientific strategy and building of the company's portfolio in targeted immunotherapies. Prior to this, Dr. Dornan was the head of Oncology Research at Gilead, identifying, validating, and translating oncogenic targets into actionable entities with biologic and small molecule therapeutics and oversaw the integrated oncology strategy team. He began his career at Genentech, where he spent 10 years serving in positions of increasing responsibility and played key roles in target discovery and validation, as well as translational research programs. Dr. Dornan received his Ph.D. from the University of Dundee in Molecular Oncology and Biochemistry and completed a postdoctoral fellowship at Genentech. Support the Show.

In this episode of Causes or Cures, Dr. Eeks chats with Dr. Valter Longo about his latest research on the fasting-mimicking diet (FMG) and how it has been shown in studies to reduce biological age and disease risk. In great detail, he describes the fasting-mimicking diet and its components while explaining how it was tested in clinical trials for its effect on biological age and disease risk. Dr. Longo describes the difference between biological age and chronological age and how he and his team measured biological age in the studies. Not attributing the benefits of the fasting-mimicking diet to weight loss alone, Dr. Valter offers theories for how it reduces biological age. Importantly, he comments on the controversial fasting study that suggests 8-hour-time-restricted eating is linked to a 91% higher risk of death from heart disease and closes by telling us what he thinks is the best fasting protocol and why. Dr. Longo  is a professor of gerontology and biological sciences and director of the Longevity Institute at the University of Southern California, a leading center for research on aging and age-related diseases. He also serves as the Director of the Longevity and Cancer Program at the Institute of Molecular Oncology in Milan, Italy. He is author of the internationall best-selling book, The Longevity Diet.  Holding a PhD in biochemistry from UCLA, his research focuses on the mechanisms of aging, including dietary and genetic interventions to slow biological aging. Read more about him here. You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTokSUBSCRIBE to her monthly newsletter here.Support the Show.

In this crucial episode of our podcast, we are joined by Dr. Valter Longo, a visionary and pioneer in cancer research, director of the Cancer Program at the IFOM Institute of Molecular Oncology in Milan, and a recipient of the Nathan Shock Lecture Award and by the American Federation for Aging Research (AFAR). Dr. Longo offers his unique expertise to unveil how protein influences cancer and what are the best protein sources for those looking to not only survive, but thrive after a cancer diagnosis.Together, we will discover which foods should be limited and which should be included in our daily diet to optimize our health and minimize the risks associated with cancer. Additionality, Dr. Longo will delve into the revolutionary concept of the fasting mimicking diet, a technique that mimics the effects of fasting while allowing food intake, explaining how this practice can significantly benefit cancer patients.Don't miss this episode full of valuable insights and practical tips on how proper nutrition and fasting strategies could be your best allies in the fight against cancer. Join us and start making informed decisions about your health and wellness with the guidance of expert Dr. Valter Longo.https://www.facebook.com/CocoMarchNMDhttps://www.instagram.com/cocomarch.nmd/https://www.youtube.com/channel/UCyT1tdUjfnbA-4Cqrz8BwFghttps://blog.dracocomarch.comhttps://store.dracocomarch.com/es/https://podcast.comocurar.com/

In this enlightening episode of the H.V.M.N. Podcast, host Dr. Latt Mansor welcomes a distinguished guest, Dr. Walter Longo, a world-renowned expert in the fields of gerontology and biological sciences. Holding prestigious positions as the Edna M. Jones Professor of Gerontology and Biological Sciences and the Director of the Longevity Institute at the University of Southern California, Leonard Davis School of Gerontology, Los Angeles, Dr. Longo is at the forefront of aging and age-related disease research. Additionally, his role as the Director of the Longevity and Cancer Program at the IFOM Institute of Molecular Oncology in Milan, Italy, places him at the cutting edge of longevity research on a global scale. Throughout the conversation, Dr. Longo delves into the intriguing distinctions between the fast mimicking diet and traditional fasting methods. The discussion prompts an essential question: Why invest in a diet plan when the alternative could be as simple as not eating? Dr. Longo provides compelling insights into how the fast mimicking diet not only offers a structured approach to fasting but also how it can be a powerful tool in combating various health issues such as cancer, diabetes, Alzheimer's, and autoimmune diseases. Moreover, Dr. Longo shares invaluable advice on living a long and healthy life, making this episode a must-listen for anyone interested in longevity, nutrition, and overall well-being. Whether you're a long-time follower of fasting practices or new to the concept of the fast mimicking diet, this episode is packed with information that could revolutionize your approach to health and longevity.   More on Dr. Longo https://www.valterlongo.com/ Twitter: https://twitter.com/hvmn and https://twitter.com/LattMansor Instagram: https://www.instagram.com/hvmn/ and https://www.instagram.com/lattmansor/ TikTok: https://www.tiktok.com/@hvmn and https://www.tiktok.com/@lattmansor Feedback form: https://forms.gle/7KH87sEqaRa1z19B6   H.V.M.N. Podcast Fam: We're giving you an exclusive offer. You are some of our most loyal fans, and we want to give you a special reward. Use HVMNPOD20 to get 20% off your next H.V.M.N. order.

Dr. Pankaj Karande is an Associate Professor in Chemical and Biological Engineering at Rensselaer Polytechnic Institute. Pankaj was trained as a chemical engineer, and his research aims to apply engineering approaches and technology to solve problems in biology and healthcare to improve the quality and quantity of human life. Projects in his lab span areas such as drug discovery, drug delivery, biomaterials, diagnostics, and more. When he's not working, Pankaj loves to cook, and experimenting with different recipes has been a great way to relieve stress. He was awarded his B.S. in Chemical Engineering from Mumbai University Institute of Chemical Technology and his Ph.D. in Chemical Engineering from the University of California, Santa Barbara. Pankaj was awarded an Anna Fuller Postdoctoral Fellowship in Molecular Oncology, and he conducted postdoctoral research in the Center for Cancer Research at Massachusetts Institute of Technology before joining the faculty at Rensselaer. Pankaj has received a variety of awards and honors in his career, including the Excellence in Classroom Instruction Award and the Outstanding Teaching Award from Rensselaer Polytechnic Institute. He also received the Alzheimer's Association New Investigator Research Award, the Goldhirsh Brain Tumor Research Award, and a Bronze Edison Award in the Best New Product in Science and Medical Category. In addition, he has been issued multiple patents in the areas of Transdermal Formulation Discovery and Novel High Throughput Screening Platforms. In our interview, Pankaj shares more about his life and science.

You've probably heard about intermittent fasting, where you don't eat for about 16 hours each day and limit the window where you're taking in food to the remaining 8 hours.But there's another type of fasting, called fasting-mimicking diet, with studies pointing to important benefits for health and longevity. For today's episode, I chatted with Dr. Valter Longo, a biogerontologist at the University of Southern California about all kinds of fasting, and particularly the fasting-mimicking diet, and strategies for making these approaches especially beneficial while minimizing really bad hunger as much as possible.If you've ever spent more than a few minutes looking into fasting, you've almost certainly come upon the name Valter Longo. Dr. Longo is the author of the bestselling book, The Longevity Diet, and he is the best known researcher of how to do a fasting-mimicking diet, as well as researching the benefits.A quick primer is helpful background for listening to this episode: with intermittent fasting, your body might begin to switch up its fuel type. Your body's usually running on carbs you get from food, which gets turned into glucose, but without food, your liver starts making something called ketones, which are these molecules that are more efficient than glucose and good for the body in various other ways.But in addition to intermittent fasting, there's an alternative that could offer more benefits to your health and boost your longevity. This is the fasting-mimicking diet, the one researched by Dr. Longo, where you go for several days eating only the types of food that, in a way, keep themselves secret from your body. So at the level of your cells, the body still thinks that it's fasting. This is the best of both worlds – you're not completely starving because you do get to have some food, and you're getting some of the amazing benefits that come with letting a fast run longer than you'd have with intermittent fasting.This episode really explores the science of fasting. Dr. Longo talks about his extensive research on why this might be one of the best things you can do for health. He's the director of the Longevity Institute in USC's Leonard Davis School of Gerontology, and the director of the Longevity and Cancer program at the IFOM Institute of Molecular Oncology in Milan. In addition, Dr. Longo is the founder and president of the Create Cures Foundation in L.A., which focuses on nutrition for the prevention and treatment of major chronic illnesses. He authored the bestelling book, The Longevity Diet. v2 In 2016, he received the Glenn Award for Research on Aging, which was based on the discovery of both genes and dietary interventions able to regulate aging and prevent diseases, among many other awards. Dr. Longo received his PhD in biochemistry from UCLA and completed his postdoc in the neurobiology of aging and Alzheimer's at USC.Check out the episode page to see the show links - www.leaps.org/heart-healthy-diet/Leaps.org is a not-for-profit initiative that publishes award-winning journalism, popularizes scientific progress on social media, and hosts events about bioethics and the future of humanity. Visit the platform at www.leaps.org. Podcast host Matt Fuchs is editor-in-chief of Leaps.org.

About this episode: David Dornan is the Chief Scientific Officer of Elevation Oncology, a clinical-stage biotech company developing targeted cancer therapeutics, with a focus on antibody drug conjugates. David brings to Elevation over two decades of industry and academic oncology drug discovery and development experience. His research spans multiple therapeutic modalities targeting cancer susceptibilities and modulating the immune system to translate into meaningful therapeutic interventions for patients. As Chief Scientific Officer, he is responsible for scientific strategy and building of the company's portfolio in targeted immunotherapies. Before leading these efforts at Elevation Oncology, David was the CSO at Bolt Biotherapeutics. Prior to this, he was the head of Oncology Research at Gilead. David began his career at Genentech, where he spent 10 years serving in positions of increasing responsibility and played key roles in target discovery and validation, as well as translational research programs.David received his Ph.D. from the University of Dundee in Molecular Oncology and Biochemistry and completed a postdoctoral fellowship at Genentech. In this episode, we discuss Elevation's ongoing clinical development of antibody-drug conjugate molecules to treat cancer and David's wealth of experience in biotech and pharma.Hosted by Joe Varriale.

In this episode I'm continuing my investigations into the science of nutrition and health. Today I'm looking at the effect that diet has on longevity. We know that eating poorly can kill you in any number of ways, but is there a fountain of youth out there? Can we extend lifespan merely by choosing the right foods?  My guest today will have something to say on this topic.   Dr. Valter Longo has thirty years of experience in the field of longevity and healthy eating. He is the Director of the Longevity Institute at the University of Southern California – Leonard Davis School of Gerontology, Los Angeles, and the Director of the Longevity and Cancer Program at the The Italian Foundation for Cancer Research Institute of Molecular Oncology in Milan, Italy. He is the author of the best seller “The Longevity Diet” and the 2 Italian books “Alla tavola della longevità” (“At the Table of Longevity”), and “La longevità inizia da bambini” (“Longevity Begins in Childhood”). Professor Longo is also the scientific director of the Create Cures Foundation and the Valter Longo Foundation. In 2018, TIME Magazine named Professor Longo as one of the 50 most influential people in health care for his research on fasting-mimicking diets as a way to improve health and prevent diseases. Please help me to spread the Rational View at patron.podbean.com/TheRationalView Join the Facebook discussion @TheRationalView Twitter @AlScottRational #TheRationalView #podcast #fasting #health #longevity #ProLon

Valter Longo is an Italian-American biologist and gerontologist who is a professor of gerontology and biological science at the University of Southern California. He is the director of the USC Longevity Institute and the Program on Longevity and Cancer at IFOM (FIRC Institute of Molecular Oncology) in Milan, Italy. Longo is known for his research on the biological mechanisms of aging, and for his work on fasting-mimicking diets, which he claims can promote health and longevity. He has written several books on the subject, including "The Longevity Diet" and "The Fasting Diet". Longo advocates for periodic fasting as a way to promote overall health and prevent disease. He believes that intermittent fasting, which involves limiting food intake to certain times of day or certain days of the week, can help reduce inflammation, improve metabolic health, and promote cellular repair and regeneration.   In today's episode, we focus on intermittent fasting. 

0:00 - THE GREAT DISINTEGRATION: Chicago mayoral poll   14:17 - Dr. Arthur Turovets, the president and founder of NJDiet, specializing in natural health and wellness, discusses safe ways to lose weight as we head towards spring and warmer weather. Discover your new healthy life plan with an extensive, on-going weight management membership today! Visit njdiet.com   23:00 - Dan & Amy return the mayor's race as Paul Vallas and Brandon Johnson gather endorsements   30:53 - Tucker Carlson on J6, Day 2   01:13:00 - Roger D Klein, MD, JD, expert with the Regulatory Transparency Project's FDA and Health Working Group. Former Director of Molecular Oncology at the Cleveland Clinic, former advisor to the FDA, CDC, CMS, and HHS, discusses the origins of COVID and the communication issues that continue to befall our health agencies. You can follow Dr. Klein on twitter @RogerDKlein   01:30:46 - Noted economist Stephen Moore on the Fed's aggressive plan for interest rate hikes. Get more from Steve @StephenMoore   01:44:03 - Senior Contributor for American Greatness, Julie Kelly, joins in on the dismantling of the Jan 6 narrative    Get Julie's book for more Jan 6 coverage  January 6: How Democrats Used the Capitol Protest to Launch a War on Terror Against the Political Right 02:05:33 - SPORTS & POLITICS: Reddick vs. PerkinsSee omnystudio.com/listener for privacy information.

On this week's episode of The Metabolic Link, we're sitting down with world-renowned Fasting and Longevity Researcher, Valter Longo, PhD, to explore a variety of topics related to metabolic health including the impact of protein consumption on longevity, the latest research on the fasting mimicking diet in diabetes and Alzheimer's, the future of metabolic therapies, and how both our host of The Metabolic Link, Dr. Dominic D'Agostino, and Dr. Longo utilize fasting and approach healthy eating in their own lives. Dr. Valter Longo has thirty years of experience in the field of longevity and healthy eating. He is the Director of the Longevity Institute at the University of Southern California – Leonard Davis School of Gerontology, Los Angeles, and the Director of the Longevity and Cancer Program at the IFOM, The Italian Foundation for Cancer Research (FIRC) Institute of Molecular Oncology in Milan, Italy. He is the author of the best seller “The Longevity Diet” and the 2 Italian books “Alla tavola della longevità” (“At the Table of Longevity”), and “La longevità inizia da bambini” (“Longevity Begins in Childhood”). Professor Longo is also the scientific director of the Create Cures Foundation and the Valter Longo Foundation. In 2018, TIME Magazine named Professor Longo as one of the 50 most influential people in health care for his research on fasting-mimicking diets as a way to improve health and prevent diseases.In every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!In every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!You can find us on all your major podcast players here and full episodes are also up on our Metabolic Health Summit YouTube channel, Apple, Google, Spotify, Amazon Music, and Buzzsprout.Thanks for listening! Follow us on social media @metabolichealthsummit for the latest science on metabolic health and therapy. Please keep in mind: The Metabolic Link does not provide medical or health advice, but rather general information that does not serve as a substitute for a licensed healthcare professional. Never delay in seeking medical advice from an appropriately licensed medical provider for any health condition that you may have.

Unprecedented dissent in China over severe COVID-19 restrictions, as demonstrators clash with police . But will the government quash protesters' anger with force or change its policy to appease the people? Guests: Dr Lawrence Young Professor of Molecular Oncology at Warwick Medical School Victor Gao Chair Professor of Soochow University Duncan Bartlett Research Associate at SOAS China Institute Colin Alexander Political Communications Lecturer at Nottingham Trent University

In this episode, we explore Dr Joe Worrall's path to landing a PhD in molecular oncology, and how he decided to pursue a career in medical writing/publishing in the pharmaceutical industry, including his side hustle: The Examiners. Automatic Question & Flashcard Generator - The Examiners The Examiners is a web-tool that Joe himself coded and allows university students to generate flashcards tailored to their own course content! Join us to hear how he was able to engineer this, navigate his PhD with all its technical challenges, and his thoughts on the medical publishing industry.

“What if I were to have someone who looked like me, worried about my mental health when I was a child? How much better of a human would I be now? How many of those internal doubts that I had would be eliminated? And I wanted to be one of those people who really drove the conversation and utilized every ounce of my influence to really create something that can revolutionize what's accessible in terms of mental health.” - Dr. Russell Ledet MD PHD MBA   On December 14, 2019, 15 African American medical students from Tulane University School of Medicine posed in front of a former slave cabin at the Whitney Plantation in Edgard, Louisiana, while donning their white coats. “We are truly our ancestors' wildest dreams,” said a tweet of one of the photos. The image went viral and multiple national news outlets picked up the story.   The students formed The 15 White Coats organization,  a nonprofit group with a threefold mission: To reimagine cultural imagery in learning spaces, lessen the financial burden of medical school for applicants of color, and influence cultural literacy in learning spaces. Donations and the sale of photographs and posters allow The 15 White Coats to distribute their photos to classrooms across the U.S., establish scholarships, and more.   Master Certified Coach Jill Farmer welcomes Dr. Russell Ledet, MD, PhD, MBA to talk about the barriers and doubts he faced as a black man and aspiring physician along his journey from security guard to MD PhD MBA. Specifically, Dr. Ledet shines light on the disadvantages that medical school applicants from marginalized communities face. In recognition of how important it is to have role models, Dr. Ledet encourages listeners to take action. He is receiving national recognition for starting 15 White Coats. Dr. Ledet talks about his journey from being in the military to becoming a security guard to realizing that he could go to college, and eventually to medical school after earning his PhD at NYU. He is a native of Lake Charles, Louisiana.    Dr. Ledet earned his bachelors degree from Southern University and Agricultural and Mechanical College at Baton Rouge. He earned his PhD in Molecular Oncology from NYU School of Medicine, Sackler Institute of Graduate Biomedical Sciences. He earned his MD and MBA from Tulane University. He is a Triple Board Resident (Pediatrics/Psychiatry/Child and Adolescent Psychiatry) at Indiana University School of Medicine. LinkedIn: Dr. Russell J. Ledet  https://www.linkedin.com/in/rjledet Instagram: @drrussellledet Find @the15white coats on Twitter, Instagram, Facebook, and LinkedIn Dr. Russell J. Ledet, MD, PhD, MBA  co-founded The 15 White Coats, an organization that helps to propel underrepresented minority students to the next levels of education by providing inspiration and economic support. Dr. Ledet has been featured on CNN, MSNBC, People Magazine, NPR, Washington Post, The Steve Harvey Show, and Good Morning America. Following medical school, he plans to focus on mental health accessibility for marginalized communities. He is a husband of 14 years to Mallory Alise, and the father of two little girls, Maleah Ann and Mahlina Abri.   Socials: @drrussellledet (IG/TikTok); FB     Find full transcripts of DocWorking: The Whole Physician Podcast episodes on the DocWorking Blog  The past few weeks have been busy at DocWorking! We have been working behind the scenes to add even more CME credits to the THRIVE memberships.    Let your CME budget help you prioritize your own wellness so you can get on with living your best life on your own terms, as defined by you, with DocWorking THRIVE.   You can take the first step today by taking our 2 Minute Balance to Burnout Quiz! Where are you on the Balance to Burnout Continuum? Take the quiz and find out today!   DocWorking empowers physicians and entire health care teams to get on the path to achieving their dreams, both in and outside of work, with programs designed to help you maximize life with minimal time.   Are you a physician who would like to tell your story? Please email Amanda Taran, our producer, at podcast@docworking.com to be considered.   And if you like our podcast and would like to subscribe and leave us a 5 star review, we would be extremely grateful!   We're everywhere you like to get your podcasts! Apple iTunes, Spotify, iHeart Radio, Google, Pandora, Stitcher, PlayerFM, ListenNotes, Amazon, YouTube, Podbean   You can also find us on Instagram, Facebook, LinkedIn and Twitter.    Some links in our blogs and show notes are affiliate links, and purchases made via those links may result in payments to DocWorking. These help toward our production costs. Thank you for supporting DocWorking: The Whole Physician Podcast!   Occasionally, we discuss financial and legal topics. We are not financial or legal professionals. Please consult a licensed professional for financial or legal advice regarding your specific situation.   Podcast produced by: Mara Heppard

Is it too much to expect health care to deliver delightful experiences? Dr. Koen Kas doesn't think so, and his vision includes digital twins, personal data stores and preventive medicine. He is a health care visionary, digital health and biomarker expert, health-tech entrepreneur, Professor of Molecular Oncology and Digital Health at the University of Ghent, international keynote speaker and author of Sick No More and Your Guide to Delight. Host Alex Maiersperger and Kas talk about the concept of delight thinking, an approach that requires stakeholders to think outside the box – creating new health care delivery models, never imagined. Kas explains the fundamental difference between design thinking and delight thinking. Delight thinking has the patient at its core, rewarding health care systems for keeping patients healthy. Kas also speaks about the role of a digital twin for the future of health care and how far we are in the development. The twin is a full representation of the holistic health of a human, combining all health data from different sources into an avatar. Testing preventive or clinical measures on the avatar will enable a visualization of health outcomes, before implementing them on the human. Health care by default is another health care concept Kas introduces during the episode, including seamless health care via sensors in homes and automatic alerts to medical professionals.Finally, he emphasizes the key to prevention and personalized medicine is data integration and encourages health care systems to reward providers and citizens for preventing, predicting and reversing diseases.  

Stefano Casola, IFOM the FIRC Institute of Molecular Oncology, Milan ITALY speaks on "B cell receptor influence on lymphoma immune surveillance in preclinical models of aggressive B cell lymphomas".

“You don't have to change yourself culturally to be brilliant,” asserts Dr. Russell Ledet, a Black U.S. Navy veteran who has earned an MD-MBA as well as a PhD in Molecular Oncology and Tumor Immunologyand now works to remove barriers for those who want to follow in his footsteps. In this fascinating interview with host Dr. Rishi Desai, learn how Dr. Ledet went from being a security guard in a hospital, to a medical student at that same hospital, to starting The 15 White Coats, an effort sparked by an unforgettable photo taken at a former slave plantation. The group, which provides funding and other support to aspiring Black physicians, has grown rapidly and garnered international attention in its short life. Tune in to learn how Ledet's 9-year-old daughter provided the spark for the project, marvel at his remarkable personal journey, and learn why having more Black physicians will improve health outcomes.Mentioned in this episode: https://www.the15whitecoats.org

Nikita Mehra (@DrNikitaMehra) is an Associate Professor at Medical Oncology and Researcher in Molecular Oncology in the Cancer Institute (WIA), Chennai, India.

0:00 - John Anthony fills in for the vacationing Dan Proft   15:14 - Amy and John react to Richard Irvin's new “nightmare” campaign ad   27:35 -An act of racism or just plain stupid?   35:04 - Amy and John take caller reaction to the Whitney Young professor's racially charged doll display    43:00 - Chris Butler, pastor and candidate for Illinois' first congressional district, discusses his recent endorsement from SBA-List.org. For more on Pastor Chris' run for congress - electchrisbutler.com   58:42 - Former Director of Molecular Oncology at the Cleveland Clinic and former advisor to the FDA, CDC, CMS, and HHS, Roger D Klein, MD, JD, explains the second booster shot and whether you'll really need it or not   01:18:59 - Bob & Michelle Snyder share the story of the daughter Jenny, which led them to start The Jennifer Lynn Snyder Teen Heart Foundation - Preventing Sudden Cardiac Death in Youth    01:31:14 -  Chief Political Writer at Spiked, Brendan O'Neill:  Why Hunter Biden's laptop really matters. Check out Brendan's latest here 01:47:56 - Paris Dennard, RNC National Spokesperson & Director of Black Media Affairs, takes on the record high gas prices across the nation. You can follow Paris on twitter @PARISDENNARD See omnystudio.com/listener for privacy information.

Dr. Daniel Rosenberg, professor of medicine, Health Net Inc. Chair in Cancer Biology, and investigator in UConn Health's Center for Molecular Oncology, is on the trail of the connection between our digestive system's microbiome and colon cancer. His research has shown how walnut consumption can impact gut bacteria in a way that seems to fight off inflammation in some people. He's also investigating why colon cancers are turning up more in younger people, in their 40s and even 30s. (March 2022, Daniel Rosenberg, Carolyn Pennington, Chris DeFrancesco) Daniel W. Rosenberg, Ph.D., faculty profile https://facultydirectory.uchc.edu/profile?profileId=Rosenberg-Daniel UConn Health Center for Molecular Oncology https://health.uconn.edu/molecular-oncology/ Walnut study https://starr.uchc.edu/Study/StudyDetails.aspx?ID=1796 gajewska@uchc.edu, pappleton@uchc.edu Peanut study https://starr.uchc.edu/Study/StudyDetails.aspx?ID=1704 nfan@uchc.edu Masako Nakanishi, Ph.D., Center for Molecular Oncology https://facultydirectory.uchc.edu/profile?profileId=Nakanishi-Masako John Birk, MD, chief, UConn Health Division of Gastroenterology https://facultydirectory.uchc.edu/profile?profileId=Birk-John Haleh Vaziri, MD, UConn Health gastrotenterologist https://facultydirectory.uchc.edu/profile?profileId=Vaziri-Haleh George Weinstock, Ph.D., The Jackson Laboratory for Genomic Medicine https://facultydirectory.uchc.edu/profile?profileId=Weinstock-George

Tune in to this episode of the Ask AI podcast as host Jaxson Khan sits down with Dr. Samuel Aparicio, the Chair in Breast Cancer Research at the University of British Columbia (UBC) and Head of the BC Cancer Research Institute Department of Breast and Molecular Oncology to ask the question: How can AI be used to help predict breast cancer? Get all the links from our episode post: https://www.askai.org/post/e37-how-is-ai-being-used-to-help-predict-breast-cancer Farewell, Jaxson! This is an especially poignant show because it's also Jaxson Khan's farewell interview with the Ask AI podcast. We cannot thank Jax enough for inspiring this podcast and being such an awesome and generous volunteer at our show. He has been a passionate supporter of Canada's Artificial Intelligence sector for many years and we wish him nothing but the best of luck in the future! We'll miss you lots Jax, please stay in touch!

Andrew Pierce talks to professor Lawrence Young, Virologist and Professor of Molecular Oncology at Warwick Medical School about why Boris Johnson's announcement to relax Covid restrictions might have come too soon, and to former Metropolitan Police Superintendent, Leroy Logan, about Cressida Dick's problem with public confidence in the police. Plus, tips on how to survive rising energy bills. See omnystudio.com/listener for privacy information.

The hero rabbi held hostage in his Texas synagogue has credited active-shooter training for helping him save his congregants — revealing Monday that he threw a chair at the terrorist so they could finally escape. Student receives praise for bogus paper on how milk is a ‘colonizer' of coffee Stephen Colbert and Senator Elizabeth Warren want to abolish the Senate Roger D Klein, MD, JD is an expert with the Regulatory Transparency Project's FDA and Health Working Group. Former Director of Molecular Oncology at the Cleveland Clinic, former advisor to the FDA, CDC, CMS, and HHS Stephen Moore is a Noted Economist, Wall Street Journal columnist and author of Trumponomics: Inside the America First Plan to Revive Our Economy. He joined Dan and Amy with reaction to Jerome Powell's comments on the national debt. Backlash as US billionaire dismisses Uyghur abuse Jon Gabriel is an Editor-in-Chief at Ricochet and contributor to AZCentral. He joined Dan and Amy with a retrospective on President Biden's first year in office. Jon says Most voters agree that they don't like him See omnystudio.com/listener for privacy information.

The last week of the year is seeing an unprecedented wave of infections across the globe as the latest COVID-19 variant surges, straining health systems. The World Health Organization (WHO) is warning of a 'tsunami of cases' worldwide. Global infections have more than doubled this week, with more than one and a half million positive cases a day. The lightning fast spread is being attributed to the highly transmissible Omicron strain. But the previous variant of concern, the Delta, hasn't gone away, and with both circulating at the same time, the WHO says it is very concerned. Guests: Dr Angelique Coetzee Chairperson of the South African Medical Association Dr Lawrence Young Professor of Molecular Oncology at Warwick Medical School Irene Petersen Professor of Epidemiology at University College London

The first study into the Omicron variant is out and scientists fear it could outcompete Delta and soon become the dominant strain. Scientists working for Africa Health Research Institute also concluded that the vaccine provides less protection against the new variant. So, will this new strain set off another wave? Or is it weak enough that the world is well prepared to deal with it? Guests: Dr Lawrence Young Professor of Molecular Oncology at Warwick Medical School Oksana Pyzik Lecturer at UCL School of Pharmacy Dr Bharat Pankhania Senior Clinical Lecturer at Exeter University Medical School

Today's Guest is Dr. Valter Longo. He has thirty years of experience in the field of longevity and healthy eating. He is the Director of the Longevity Institute at the University of Southern California and the Director of the Longevity and Cancer Program at the Italian Foundation for Cancer Research's Institute of Molecular Oncology in Milan, Italy. In 2018, TIME Magazine named Professor Longo as one of the 50 most influential people in health care for his research on fasting-mimicking diets as a way to improve health and prevent disease. He's also the best-selling author of The Longevity Diet. In this episode we discuss the main causes of people not having longevity, what the longevity diet is and why it works, the five pillars of longevity and so much more!For more go to: www.lewishowes.com/1199Get Dr. Longo's book - https://www.valterlongo.com/the-longevity-diet/Mel Robbins: The “Secret” Mindset Habit to Building Confidence and Overcoming Scarcity: https://link.chtbl.com/970-podDr. Joe Dispenza on Healing the Body and Transforming the Mind: https://link.chtbl.com/826-podMaster Your Mind and Defy the Odds with David Goggins: https://link.chtbl.com/715-podSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The emergence of a new coronavirus variant, Omicron, has put the world on high alert. It's been two years since the beginning of the pandemic, and just when there were signs of a return to some sort of normalcy, the new variant has caused concerns among health professionals. After scientists in South Africa announced its discovery, it wasn't long before the United States, the United Kingdom, European Union, and other countries began imposing travel restrictions. So, how is this variant different from Delta? Should the world be worried? Guests: Dr Mvuyisi Mzukwa Vice Chairperson of the South African Medical Association Oksana Pyzik UCL School of Pharmacy Senior Teaching Fellow Dr Lawrence Young Professor of Molecular Oncology at Warwick Medical School

Jim White, in for Andrew Pierce, talks to Dr. Lawrence Young, Virologist and Professor of Molecular Oncology at Warwick Medical School about the threat the new South African COVID variant poses to the world, and talks to Jenna Veerapen, Senior Therapist at the UK Addiction Treatment Group, about how the lack of face-to-face contact with healthcare workers in the last year has led to a shocking increase in deaths among alcoholics and drug addicts. Plus, how to check whether your cat is a psychopath. See omnystudio.com/listener for privacy information.

There's been a resurgence of COVID-19 cases in Germany and parts of Eastern Europe. The World Health Organization (WHO) has warned that the continent could be headed towards a deadly winter season. The COVID-19 has so far killed more than five million people the world over and as per the WHO, another 500,000 Europeans could lose their lives to the virus. With such high vaccination rates, why is then the situation still so critical in Europe? Guests: Dr Annelies Wilder-Smith Professor at the London School of Hygiene and Tropical Medicine Dr Bharat Pankhania Senior Clinical Lecturer at Exeter University Medical School Dr Lawrence Young Professor of Molecular Oncology at Warwick Medical School

1:01 -Vice President of the Kathryn and Shelby Cullom Davis Institute for International Studies at The Heritage Foundation, Lt Col James Carafano, reviews Joe Biden's CNN Townhall performance Check out Jim Carafano's new book Brutal War: Jungle Fighting in Papua New Guinea, 1942here 1:21 -Roger D Klein, MD, JD,  expert with the Regulatory Transparency Project's FDA and Health Working Group. Former Director of Molecular Oncology at the Cleveland Clinic, former advisor to the FDA, CDC, CMS, and HHS, says fear is driving the push to vaccinate healthy children For more on Dr. Klein – rogerdklein.com 1:38 -George Richter is a Bristol Kendall Fire Protection District firefighter who was fired for insubordination More on George's story here 1:55 -Thomas DeVore, attorney with Silver Lake Law, Ltd, is representing 145 school districts against Illinois' COVID restrictions  More on the lawsuit here See omnystudio.com/listener for privacy information.

Martha is a Registered Dietitian in Ontario, Canada, with over 30 years of experience working in many areas of nutrition. She currently works in Long Term Care (nursing homes, gerontology) and has a private practice, Primal RD, promoting a LCHF diet and lifestyle for healthy aging and chronic disease prevention.  And she is a cancer survivor who, after many months of research on “her kind of cancer” (Stage 1C ovarian cancer) discovered that diet could play a big role in supporting her through the chemotherapy she was facing. Note: This is not a cure for cancer and Martha's regimen did not prevent her hair from falling out. We are also not giving medical advice here. If you want to learn more about Martha's protocol, start with her blog and I recommend the book. It contains all of her research as well as recipes and her exact diet for the time during her weeks of chemo. I'll let her tell you her story (transcript below or have a listen, it starts about minute 5) But it starts with a perfectly healthy 58-year-old with not so much as an ache or a single medication. As do most of when we have a symptom or diagnosis, Martha consulted Dr. Google and https://pubmed.ncbi.nlm.nih.gov/ (Pubmed) to learn as much about her kind of cancer and what, if anything, she could do lifestyle wise that might help.  “It turns out that the metabolism of cancer to other cells or cancer tumors is different. The way that they burn fuel is different than healthy cells. And anytime you're talking about metabolism or fueling your body, then you're back to nutrition because that's how we fuel our body.”“And I knew nothing about this. I mean, I've been a dietician for 35 freaking years, and I didn't know that there was anything that we could do about cancer, and that pissed me off, really. Why not, you know?” Cancer is a greedy hog when it comes to glucose uptake from the blood and its exaggerated rate of metabolism has been known for a long time. Again, why don't more people hear about this? Most of what Martha had recommended—and many cancer docs and nurses will as well—is give the chemo patients anything they can keep down to keep their weight up. Usually, it's a starchy thing like toast or soda, cookies. All the absolute wrong things to feed a cancer patient if they feed on sugar. Did you know that cancer cells, unlike healthy cells, cannot turn themselves down or off? So healthy cells can upregulate or down regulate their energy needs based on the fuel supply that's available. If you're starving or fasting, or even overnight when you're sleeping, your body cells can quiet themselves down. Why this matters is that chemo is looking for cancer cells, super active, always “on” and hungry for sugar. If you quiet down the healthy cells there is less chance of them being killed off. The chemo won't find them. Martha also realized that the nutritional interventions that keep blood sugar levels low and steady will make it harder for cancer to get what it needs to grow. Her research brought her to https://www.valterlongo.com/ (Dr. Valter Longo), who it turns out, is a super interesting guy. Not to mention, he is the Edna M. Jones Professor of Gerontology and Biological Sciences and Director of the Longevity Institute at the University of Southern California –Leonard Davis School of Gerontology, Los Angeles, one of the leading centers for research on aging and age-related disease. Dr. Longo is also the Director of the Longevity and Cancer Program at the IFOM Institute of Molecular Oncology in Milan, Italy. I include all of that to show that this isn't some flake with a theory about sugar and cancer. He has written a few books if you are interested in the nutrition side of boosting your aging better protocols. But I digress… Martha told me, “What Dr.Longo proved with his research is that number one, fasting does not negate the effect of chemo in any way, if anything, it potentiates it, it makes it more potent....

Dr. Clare Grace, Chief Patient Officer at Parexel, a leading Clinical Research Organization (CRO) discusses a report titled "Discussions on Diversity" that includes key takeaways regarding candid discussions on the topic of racial and ethnic diversity in clinical trials. As Chief Patient Officer for Parexel, Dr. Grace leads Parexel's global patient advocacy and site efforts, including patient engagement strategies and efforts to enhance clinical trial diversity as well as new, innovative approaches to help teams and customers work more effectively with investigative sites. Most recently she served as Vice President, Site & Patient Access at Syneos Health, formerly INC Research, where she oversaw all departments responsible for patient engagement, feasibility, site identification, strategic site relations and investigator payments. Her experience also includes senior-level patient and site-focused leadership roles with PPD, Astra Zeneca and Antisoma. With more than 20 years of experience in the CRO and biopharmaceutical industries, Dr. Grace was recognized in 2018 by PharmaVoice as one of the top 100 most inspirational leaders in the pharmaceutical industry. She earned a doctorate in Molecular Oncology from the University of Manchester Institute of Science and Technology and a bachelor's degree in applied biochemistry from Liverpool John Moores University, both in England. Dr. Grace is active in several global and national-level advisory groups, including the Society for Clinical Research Sites (SCRS) and the SCRS Leadership Council. #Parexel

The Human Immune System Basics In a time of a Covid pandemic, and the rapid development of several life-saving vaccines to address it, the world has seen the possibilities that vaccines offer. But none of this has come without something unexpected given the hundreds of thousands who have died; vaccine hesitancy. One of the primary drivers for the last 20+ years of oropharyngeal cancers has been a virus, HPV. In 2006 a vaccine was made available in the market that will prevent HPV infections in the future generation that gets vaccinated now as children. Here in our head and neck/oral cancer world, there was also a huge opportunity, marred by some vocal anti-vaccine voices that have held back, through disinformation, the full potential of this cancer-preventing technology. OCF decided that we needed not just to argue with those in opposition to all vaccines, but to educate people with solid, science-based information so that they would feel more secure protecting their children while the pre-exposure window existed to use the vaccine. This task means that first, we have to ensure that individuals have a working understanding of the immune system itself, second that they understand how it protects us from various threats, and third what we can do to educate the immune system about threats it needs to recognize and protect us, pre-infection....ie through the use of a vaccine. Hesitancy or uncertainty about vaccination can only be eliminated through a thorough understanding of it, not arguing against people who want to fight through the use of disinformation campaigns and lies. Armed with facts, the decision to be vaccinated is much easier. This first of three podcasts will give the listener a sound understanding of how our immune system works, how it defines what is a threat, and what components of it are put into action to protect us. To do this well we have enlisted the help of OCF's long-time friend and colleague, Dr. Ross Kerr from NYU to act as the OCF moderator for this episode, and he has chosen Dr. David Levy as his well-versed and informed partner in the discussion. Dr. Levy has been working in the area of immune system research for decades. It is a privilege to have both of these distinguished doctors on this podcast. We would like to mention that this podcast was produced by the Oral Cancer Foundation in partnership with our long-term partner in many endeavors, The American Academy of Oral Medicine. Dr. David Levy PROFESSOR OF PATHOLOGY AND MICROBIOLOGY Dr. Louis A Schneider Professorship in Molecular Pathology Director, Molecular Oncology and Tumor Immunology Training Program Faculty Liaison Director, Advanced Research Technologies Department of Pathology New York University School of Medicine

Dr Nicole Brooks is pure sunshine.  A beaming smile and down to earth nature that belies the gravity of the work she does… day in, day out.  You see, at 15 years of age Nicole, lost her beautiful mum, Susie, to cancer.   And she's taken that tragedy and profound loss and converted it into devoting her life to cancer research and improving the lives and health outcomes of patients.  Nicole holds a Bachelor of Science with Honours and a PHD in foetal physiology in obstetrics and gynaecology from the University of Melbourne.  And now, as the program manager of The Molecular Oncology and Cancer Immunology (MOCI) group at Epworth Healthcare, she, and her brilliant colleagues, aim to provide patients with access to cutting-edge genomic testing.Today's episode of Brave Journeys is brought to you by TIDEE – Professional Organisers – helping bring calm to your everyday.Find TIDEE on Insta here: @tideelifeBUT BEFORE YOU GO…Find out more about Nic hereFind out more about Tam hereFollow Tam on InstaFollow BRAVE JOURNEYS on InstaJoin the conversation and chat about the episode hereNEED MORE INSPIRATION?Find other BRAVE JOURNEYS episodes hereCREDITS:Creator, Host & Executive Producer: Tammi Faraday With thanks to my special guest: Dr Nicole BrooksAudio Editor: Zoltan FecsoWith very special thanks to George Weinberg.BRAVE JOURNEYS acknowledges the Traditional Owners of the Land we record this podcast on, the Yaluk-ut Weelam Clan of the Boon Wurrung who are part of the Kulin Nation. We pay our respect to their Elders, both past, present and emerging and extend that respect to all Aboriginal and Torres Strait Islander cultures.

Dr. Valter Longo is the Edna M. Jones Professor of Gerontology and Biological Sciences and Director of the Longevity Institute at the University of Southern California –Leonard Davis School of Gerontology, Los Angeles, one of the leading centers for research on aging and age-related disease. Dr. Longo is also the Director of the Longevity and Cancer Program at the IFOM Institute of Molecular Oncology in Milan, Italy.   In this episode Dr. Mike and Dr. Longo discuss the five pillars of longevity, the latest research on how fasting-mimicking diets (FMD) effect living longer, the need for FDA approved fasting standards, how to determine one’s ideal weight, how to stave off dementia and other neurological problems, and how diet relates to cancer prevention.    Professor Longo donates all profits from his books to research programs, some of which are named above. His books are made possible by his two foundations: Fondazione Valter Longo in Milano and Create Cures Foundation in Los Angeles. For more information: https://www.valterlongo.com/  https://www.valterlongo.com https://www.facebook.com/profvalterlongo/ https://www.instagram.com/prof_valterlongo/ https://www.instagram.com/stage29podcasts https://twitter.com/stage29podcasts https://www.facebook.com/Stage29Podcasts https://www.facebook.com/17daydiet/ https://www.instagram.com/17daydiet/ https://www.youtube.com/drmikediet https://www.pinterest.com/17daydiet/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a Text Message.Welcome to episode 4. of 'A Clear Voice'. In this episode, we are taking a break in discussing the issues surrounding COVID-19 as  Chadwan Al Yaghchi discusses 'The management of transgender voice.'  In this episode:1:42 Q1. What got you interested in transgender voice?2:40 Q2.  How do you approach the management? 5:47 Q3.  It certainly requires an MDT approach. Once the decision has been agreed upon for surgery can you take us through the surgical technique you employ?8:07 Q4. What are the post-op recommendations and how successful do you find the treatment package?12:05 Take home message.Guest Bio:  Chadwan Al YaghchiMr Chadwan Al Yaghchi is a consultant otolaryngologist at the National Centre for Airway Reconstruction and Imperial Voice and Swallowing Centre. He completed his higher surgical training in Ear Nose and Throat in London North Thames regional rotation. During his training, he developed an interest invoice, airway stenosis and dysphagia.  In addition to his adult service, he is an honorary consultant at The Royal Brompton and Harefield NHS Foundation Trust where he manages children with complex airway, respiratory and swallowing conditions.Mr Al Yaghchi holds a PhD in Molecular Oncology from the Queen Mary's University of London with a special research interest in oncolytic viruses in head and neck cancers. In addition, he has an active clinical research program in voice, airway and swallowing disorders.Mr Al Yaghchi is a founding member of the British Laryngological Association and served on the council since 2013. He is currently the associate honorary treasurer.Contact InformationVisit www.britishlaryngological.org or download BLA Connect from your app store for further information and details on becoming a BLA member.Email: enquiries@britishlaryngological.org for any questions or topic suggestions you may have for future episodes.This show is brought to you by the BLA, you can follow us on  Twitter, Facebook, Linkedin and Contact InformationVisit www.britishlaryngological.org or download BLA Connect from your app store for further information and details on becoming a BLA member.Register for Cutting Edge Laryngology 2024, 2-4 October 2024, at the Royal Society of Medicine London, here. Email: enquiries@britishlaryngological.org for any questions or topic suggestions you may have for future episodes. This show is brought to you by the BLA, you can follow us on Twitter, Facebook, Linkedin and Instagram hosted by Natalie Watson @surgeonsinger produced and directed by Heather Pownall of Heather's Media Hub Ltd. The opinions of our host and guests are their own; The BLA does not endorse any individual viewpoints, given products or companies. If you enjoyed this podcast, please rate, review and subscribe with the podcast provider of your choice.

Dr Valter Longo is the Edna M. Jones Professor of Gerontology and Biological Sciences and Director of the Longevity Institute at the University of Southern California –Leonard Davis School of Gerontology, Los Angeles, one of the leading centres for research on ageing and age-related disease. Dr Longo is also the Director of the Longevity and Cancer Program at the IFOM Institute of Molecular Oncology in Milan, Italy.  The Longo laboratory published key findings on a 5-day periodic dietary intervention called Fasting Mimicking Diet (FMD), and showed in randomized clinical trials that FMD reduces the risk factors and markers associated with ageing and diseases. Dr Longo's most recent studies focus on the use of FMD interventions to activate stem cell-based regeneration to promote longevity. This program can be purchased on prolonfmd.com and all profits go to charities or research.  Dr Longo has received numerous awards for his work and  In 2018 he was named by “Time Magazine” one of the 50 most influential people in health care for his research on fasting-mimicking diets as a way to improve health and prevent disease. books include the best seller “The Longevity Diet”. Conflict of interest: Professor Longo donates all of the profits from his shares in the L-Nutra company to the Creates Cures Foundation, which is dedicated to helping find low-cost lifestyle therapies for the prevention and treatment of major diseases.   If you find these podcasts valuable, rating it 5 stars and leaving a review in iTunes or Facebook is a huge help. For more podcasts and resources for both health professionals and patients including websites, courses, apps, books and more, please check out www.thegpshow.com Thank you for listening and supporting.

All morning long, Dan and Amy had the latest on the riots in downtown Chicago Lt. Col. James Carafano is Vice President of the Kathryn and Shelby Cullom Davis Institute for International Studies at The Heritage Foundation and author of  Wiki at War: Conflict in a Socially Networked World and Private Sector, Public Wars – Contractors in Combat he joined Dan and Amy to explain why he believes why Trump’s TikTok battle with China is worth fighting Roger D Klein, MD, JD is an expert with the Regulatory Transparency Project’s FDA and Health Working Group. Former Director of Molecular Oncology at the Cleveland Clinic, former advisor to the FDA, CDC, CMS, and HHS. He joined Dan and Amy to talk about the latest news in the COVID outbreak Latasha Fields is the Co-Founder and Overseer of Our Report Ministries & Publications, Founder/Teacher of Ky’Ijel Group Christian Academy (Homeschool Academy), Director of Christian Home Educators Support System (C.H.E.S.S.), State Coordinator of Illinois for ParentalRights.org. She joined Dan and Amy to talk about the state of public and private education in the wake of the COVID-19 outbreak

My guest today is a world renowned scientist and researcher Professor Valter Longo. Most well recognised for his work in the longevity field and fasting., Valter has thirty years of experience in the field of longevity and healthy eating. He is the Director of the Longevity Institute at the University of Southern California – Leonard Davis School of Gerontology, Los Angeles, and the Director of the Longevity and Cancer Program at the IFOM Institute of Molecular Oncology in Milan, Italy. He is the author of the best seller “The Longevity Diet” and is also the scientific director of the Create Cures Foundation and the Valter Longo Foundation. On today’s pod we talk aboutWhat fasting means and the different types of fastingThe longevity diet and the fasting mimicking diet (FMD), and what are their aims?Does the scientific data suggest benefit?Which are the main features of the longevity diet? How many meals should be eaten each day?Why fasting works on longevity?How does the fasting mimicking diet work?The utility of FMD in the treatment of cancer, autoimmune conditions and metabolic disorders Do check out Professor Longo's book - The Longevity Diet - it really is a very interesting read and full of such great information.Social Media LinksWebsiteFacebook Instagram See acast.com/privacy for privacy and opt-out information.

There's new evidence that intermittent fasting boosts immunity, improves cognition function, helps with weight loss, and even reverses certain diseases. How is it possible that simply restricting meal times can alter how your body functions? There are several ways to approach fasting including, intermittent fasting, alternate-day fasting, and water fasting. Yet, many people who begin a fasting regimen struggle to maintain a routine long enough to reap the benefits. So how do you choose a sustainable and healthy approach? In this episode, Dr. Weil and Dr. Maizes welcome Dr. Valter Logo, director of the Longevity Institute at the University of Southern California, the director of the Longevity and Cancer Program at the Institute of Molecular Oncology in Milan, Italy, and author of the book "The Longevity Diet". Dr. Longo explains fasting's effects on the immune system and the microbiome, discusses the various approaches, and advocates for FMD or "fasting-mimicking diet".

There are some encouraging signs around the world that the Covid-19 curve is flattening in some places, while falling in others. During the course of this pandemic we are focussing, on this podcast, less on longevity and more on our immediate futures. But as life slowly evolves towards a new normal, there are many lessons to be learned from the pandemic and the role science plays in our lives. In this episode we catch up with Prof. Valter Longo, director of the Longevity Institute at the University of Southern California and director of the Longevity and Cancer Program at IFOM Institute of Molecular Oncology in Milan in Italy. The Italian scientist splits his time between his home country and the United States, both badly affected by coronavirus. In this episode we discuss the role of scientists working alongside doctors, sharing advice on how to behave during the outbreak. We also discuss the implications for people following a fasting mimicking diet, during a time when the risk of infection by the virus is high. Earlier LLAMA podcast conversations with Prof. Longo:March 7, 2017: Creating the fasting mimicking dietJanuary 16, 2018: Living to 110 on a science-based dietIn this interview we discuss:Personal insights into the progression of coronavirus in Italy and the United States.The debate over the use of chloroquine to treat patients with Covid-19.Was time wasted in the US through the lack of advice to wear masks in the early stages of the outbreak?Speculation on why California has significantly few cases than other large population centers in the US. The work of Dr. Longo's Create Cures Foundation, including education and work to combat childhood obesity. Geographic differences in the spread of coronavirusHelping front-line health workers treating patients with coronavirus. The power of scientists and doctors working together as a team.Is it safe to go on a diet, or fast, during the coronavirus outbreak?Latest news on the Fasting Mimicking Diet and new clinical trials.The Live Long and Master Aging podcast shares ideas but does not offer medical advice. If you have health concerns of any kind, or you are considering adopting a new diet or exercise regime, you should consult your doctor.

#DoctorsUpdate #Solutions Dr Roger Klein a former HHS Advisor to FDA, CMS and CDC, and a leading authority on public policies related to the implementation of precision medicine. A physician and an attorney, Dr. Klein was previously Medical Director of Molecular Oncology at Cleveland Clinic, and has served in leadership roles in many cancer-related professional society committees, including current Chair of the Association for Molecular Pathology’s (AMP’s) Solid Tumors Division. Where did the WHO fail in their mission? What is the good news about treatment for CCP Virus and what are we learning about it? Media Madness has created this over reaction. Why were Sports Leagues allowed to push our country into a complete shut down?

#TheJEZEBELSpirit #CCPVirus Dan Perkins author speaker writer we discuss the JEZEBEL Spirit, Terrorism as a viral pandemic and the question of whether this is in fact a biochemical attack from our enemies. What about the suicide deaths and the decision by sports leagues like the NBA which led to the rest of the massive shut downs and forced cities and Governor's to issue lock down orders. The projected death toll is 63, 000 down from 2.2 million. Yes the actions taken have made a dramatic impact on the number, but was there a medium response that might have been better? How are we going to turn back on the spicket? #ChosenGold Dr Tom Barrett discusses the economy and the value of hard assets like gold in this market. Investment grade gold. #DoctorsUpdate #Solutions Dr Roger Klein a former HHS Advisor to FDA, CMS and CDC, and a leading authority on public policies related to the implementation of precision medicine. A physician and an attorney, Dr. Klein was previously Medical Director of Molecular Oncology at Cleveland Clinic, and has served in leadership roles in many cancer-related professional society committees, including current Chair of the Association for Molecular Pathology’s (AMP’s) Solid Tumors Division. Where did the WHO fail in their mission? What is the good news about treatment for CCP Virus and what are we learning about it? Rick Manning joins in as my co Host.

Peter welcomes Dr. Roger Klein to the show.  They discuss how dangerous is the Corona virus and are you in any danger? Roger D. Klein, MD, JD (@RogerDKlein) is an expert with the Regulatory Transparency Project's FDA and Health Working Group. He is the former Medical Director of Molecular Oncology at the Cleveland Clinic, a former adviser to the FDA, CDC, CMS and HHS. See omnystudio.com/listener for privacy information.

Maurizio MONGIAT, Department of Translational Research, Division of Molecular Oncology, National Cancer Institute Aviano (CRO), IRCCS, Aviano, ITALY speaks on "Multimerin-2: a gatekeeper of vascular stability". This seminar has been recorded by ICGEB Trieste.

A physician-scientist and thought leader whose research has helped change the clinical care of leukemia patients, Kevin Shannon, MD, continues to shape the field. In this conversation, Dr. Shannon takes us through the challenges and hopes of leukemia research and describes what has him most excited about the state of cancer research. Kevin Shannon, MD, is Professor in the Department of Pediatrics at the University of California, San Francisco, where he holds the Roma and Marvin Auerback Distinguished Professorship of Molecular Oncology. For his seminal research accomplishments, Dr. Shannon was named an American Cancer Society Research Professor. 2:09 – What are leukemias? 4:37 – What people should know about the state of leukemia research: “Leukemia has been one of the diseases where we’ve been able to apply the principle of understanding the underlying molecular basis of the disease to developing better treatments, and then implementing those treatments in the clinic.” 7:13 – How he decides which mutations in the DNA are the most important to study 9:53 – The difference between a DNA mutation and chromosomal abnormality, the problems they cause, and how they can even occur together 16:06 – What it means to say something is “druggable.” 18:36 – How leukemias become resistant to treatment 21:48 – How do you treat a disease that’s constantly changing? 25:12 – How his research provides insight into some of the broader questions in cancer research, beyond leukemia 27:56 – What excites him most about the state of cancer research today 32:19 – The impact of American Cancer Society funding on his career 36:35 – The outsize value of Institutional Research Grants, small pilot awards that the American Cancer Society awards to organizations such as the University of California at San Francisco 39:25 – His thoughts on the partnership between the American Cancer Society and St. Baldrick’s Foundation “to raise $11 million to fund the most innovative biological and clinical laboratory studies that have the greatest potential to quickly deliver new and improved treatments for kids with cancer.” (http://pressroom.cancer.org/StBaldricks2019) 42:26 – A message for cancer patients and caregivers

Dr. Longo is one of the leading international authorities on the topic of the role of diet in health and longevity, creator of the 5-Day Fasting Mimicking Diet, and author of the International bestselling book: The Longevity Diet: Discover the New Science behind stem cell activation and regeneration to slow aging, fight disease and optimize weight 3:5 - Age related disease and the Longevity program. 5:30 - Fasting mimicking diet vs. regular diet. 7:30 - Five day diet. 9:10 - Concerns regarding low carb diet. 19:10 - Fasting Mimicking Diet and Cancer Learn more about Medicine, We're Still Practicing and Dr. Steven Taback: https://www.curtco.com/stillpracticing And follow us: Facebook: https://www.facebook.com/curtcomedia Instagram: https://www.instagram.com/curtcomedia Twitter: https://www.twitter.com/curtcomedia A CurtCo Media Production https://www.curtco.com

Researcher Linda Malkas, Ph.D., dean of translational science and the M.T. & B.A. Ahmadinia Professor in Molecular Oncology and associate chair in the Department of Molecular and Cellular Biology at City of Hope discusses cancer research, her story, and the background of City of Hope Cancer Center.

It’s easy to think of cancer as an invader to the body. But in reality, it’s simply the result of a few proofreading errors in DNA replication that occur over time when cells divide. In Episode 3, Jane Grogan chats with Fred de Sauvage, Vice President and Staff Scientist, Molecular Oncology, about how just a handful of mutations can make normal cells go rogue, and how the field is finding new ways to stop the growth of cancer in its tracks.

Unexpected and profound insights from smart people you’d like to meet. Today my guest is Jennifer Byrne, who is Professor of Molecular Oncology at the University of Sydney and the Children’s Hospital at Westmead, in Sydney’s west. In this episode, Jennifer and I speak about her role at the Children’s Cancer Research unit, her current research interests and her scientific career. In her research, Jennifer analyses childhood and adult cancers at a molecular level, which involves working collaboratively with other researchers. In 2017 Professor Byrne was named in the international journal Nature’s top 10 "people who mattered" for her work in identifying research papers that could mislead researchers working on cancer treatments. Links to some of Professor Byrne’s research papers and articles are provided in the show notes. Here’s my conversation with Professor Jennifer Byrne. Links: http://www.kidsresearch.org.au/research/children%E2%80%99s-cancer-research-unit/molecular-oncology https://link.springer.com/article/10.1007%2Fs11192-016-2209-6 https://www.smh.com.au/healthcare/sydney-cancer-scientist-jennifer-byrne-named-as-one-of-10-people-who-matter-in-science-by-nature-20171219-h075ma.html http://sydney.edu.au/medicine/people/academics/profiles/jennifer.byrne.php https://elifesciences.org/articles/31083 Twitter https://twitter.com/jabyrnesci?lang=en

Professor Jennifer Byrne has spent her scientific career analysing childhood and adult cancers at a molecular level. Her PhD studies mapped loss of chromosome 11p15 loci in embryonal tumours, and she then identified a novel gene family during postdoctoral studies in France. Professor Byrne is Head of the Children’s Cancer Research Unit in the Kids Research Institute at the Children’s Hospital at Westmead, and Professor of Molecular Oncology in the Discipline of Child and Adolescent Health, Sydney Medical School. She was recently recognised as one of Nature's "ten people who mattered in 2017”, for exposing and large number of flawed and fraudulent genetics research papers and helping to design software to detect them.

https://www.rapamycinpress.com/blog/oncotarget/possible-new-target-breast-cancer-treatment/ Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer Oncotarget. 2017; 8:20572-20587. https://doi.org/10.18632/oncotarget.16244 Tristan Gallenne1,9, Kenneth N. Ross4,5,*, Nils L. Visser1,*, Salony4,5,*, Christophe J. Desmet1, Ben S. Wittner4,5, Lodewyk F.A. Wessels2,3, Sridhar Ramaswamy4,5,6,7,8 and Daniel S. Peeper1 1 Department of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan, CX, Amsterdam, The Netherlands 2 Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan, CX, Amsterdam, The Netherlands 3 Faculty of EEMCS Delft University of Technology, Delft, The Netherlands 4 Massachusetts General Hospital Cancer Center, Boston, MA, USA 5 Harvard Medical School, Boston, MA, USA 6 Broad Institute of Harvard & MIT, Cambridge, MA, USA 7 Harvard Stem Cell Institute, Cambridge, MA, USA 8 Harvard-Ludwig Center for Cancer Research, Boston, MA, USA 9 Current address: Merus B.V., Padualaan, CH Utrecht, The Netherlands * These authors have contributed equally Correspondence to: Sridhar Ramaswamy, email: sridhar@mgh.harvard.edu Daniel S. Peeper, email: d.peeper@nki.nl Keywords: breast cancer, metastasis, prognosis, tumor biology Received: December 14, 2016 Accepted: January 28, 2017 Published: March 15, 2017 http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=16244&path[]=51959

When Nature magazine published the top 10 researchers of 2017 there was one Australian. A radio astronomer ? no.  A paleontologist? no. She is a professor of Molecular Oncology working with the "the Post-Truth Initiative". Doctor Karl interviews our world leading researcher on how she beat fake science. "Seek and Blast" is the software she helped develop in her spare time. An uplifting story on beating the cheats.

Norris Cotton Cancer Center Grand Rounds presented on April 24, 2018 Justin M. Balko, Pharm.D. Ph.D Assistant Professor, Department of Medicine Cancer Biology Program Vanderbilt University Medical Center Leader of Molecular Oncology, Center for Cancer-Targeted Therapies Vanderbilt Ingram Cancer Center

Chad is currently pursuing post-graduate research in Molecular Oncology. He is in the process of writing a review paper on ketogenic diets and cancer, along with Brad Dieter and Tim Sharpe. Chad has spent over 19 years conducting research and developing protocols in cellular and molecular physiology. He is an adjunct faculty member at the University of San Diego, and has developed some of the most advanced blood lactate testing and intermittent hypoxia protocols in the world. He founded the Institute for Human Kinetics in 2011, where he works with many of the world’s top athletes. In addition, he was a two sport Olympic athlete. He also serves as the Human Performance Specialist at Navy Special Warfare developing programs to prepare Navy Seals for combat deployment though their Tactical Athlete Program. Chad also heads OPI’s Research Team and has the knowledge base to conduct medical and exercise physiology research in both humans and rodents. Links & Resources  Institute for Human Kinetics Lab - https://www.ihklab.com/ Facebook - https://www.facebook.com/chad.macias Instagram - https://www.instagram.com/ihk_built/    

Professor Miles Prince Biog Professor Prince is the Professor Director of Molecular Oncology and Cancer Immunology at Epworth Healthcare and the Director for the Centre for Blood Cell Therapies at Peter MacCallum Cancer centre. Miles describes himself as a translational researcher – looking for new therapies in the treatment of cancer, particularly in the way Listen In The post BC 34: Professor Miles – Genomics, cancer management – what’s the future? appeared first on The Wellness Couch.

Ahead on Biotechnology Focus Radio : Bellus Health back in the game with a new therapeutic asset, BC Cancer Agency scientists make two breakthrough discoveries, and RepliCel Life Sciences gets by with a little help from its friends. We have this and more in store for you on this week’s show. Welcome to another episode of Biotechnology Focus Radio. I’m your host Shawn Lawrence, here to give you a rundown of this week’s top stories on the Canadian biotech scene.   Our first story this week takes us to CALGARY, AB where a team of Canadian physicians and researchers are believed to be the first in the world to have used gene therapy to treat a patient with Fabry disease, a rare inherited enzyme deficiency that can damage major organs and shorten lifespan. Specifically, people with the disease have a gene called GLA that doesn’t function as it should; as a result their bodies are unable to make the correct version of a particular enzyme that breaks down a fat called Gb3. A buildup of Gb3 can lead to problems in the kidneys, heart and brain. In their experimental trial, the researchers led by Dr. Aneal Khan, a Alberta Health Services medical geneticist and member of the Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary collected a quantity of a Fabry patient’s own blood stem cells then used a specially engineered virus to augment those cells with copies of the fully functional gene that is responsible for the enzyme. The altered stem cells were then transplanted back into the patient on Jan. 11, 2017. While Dr. Khan says it’s too soon to say whether this therapy will ultimately be a long-term treatment for the disease, based on the team’s success in animal trials, he is hopeful it will be a beneficial to patients Dr. Jeffrey Medin, a researcher with the Medical College of Wisconsin and the project’s principal investigator, adds that the trial is a major step forward in treating inherited genetic diseases in adults. The treatment, which has been approved by Health Canada for experimental purposes, is also believed to be the first trial in Canada to use a lentivirus in gene therapy. In this case, the specially modified virus was stripped of its disease-causing capability and augmented with a working copy of the gene that’s responsible for the missing enzyme. The project is being funded by the Canadian Institutes of Health Research and the Kidney Foundation of Canada. The Queen Elizabeth II Health Sciences Centre in Halifax and the University Health Network in Toronto are also recruiting people with Fabry disease for the trial. In R&D news, a team of BC Cancer Agency scientists has made two exciting drug discoveries that could potentially allow for new approaches to target various cancers more specifically, through the exploitation of mutations found only in cancer cells and not normal cells. The first discovery, which has already led to a clinical trial, exploits the inability of BRCA1/2 deficient cancers to repair their own DNA. The second discovery is of a drug-like molecule that can alter the way cells translate genetic information into proteins. Both discoveries were made by Dr. Sam Aparicio, head of the Department of Breast and Molecular Oncology, and his research team at the BC Cancer Agency.The first success in this area is a discovery published in Nature Communications, where Dr. Aparicio’s team has discovered that the drug, CX-5461, originally developed for cancers of the blood and lymph system, can be repurposed as a drug treatment for breast cancer. Still early in its clinical development life cycle, CX-5461 has been shown through Dr. Aparicio’s latest work, to bind to the DNA of certain regions of the genome causing it to fold up and interrupt the DNA copying process. Thus, the compound is selectively active in tumours from patients with mutations in the BRCA1/2 gene, known to cause a strong familial predisposition to breast cancer, and account for approximately 15 per cent of the population with the disease. The study is currently in Phase 1 of a multi-centre clinical trial coordinated by Canadian Cancer Trials Group, which began in June of 2016. Phase two will accept even more patients to determine whether the activity found through preclinical studies is reflected in responses in patients. Both Dr. Aparicio and Dr. Karen Gelmon, senior scientist, medical oncologist and the clinical trial lead for the study add that if the trial is successful, they then hope to expand testing to other types of cancer in the near future. In addition to the CX-5461 findings, a second paper published in Nature Communications communicates the discovery of a different prototype drug, a compound called ‘T3’, engineered to alter the way that cells translate DNA, through splicing of RNA, into proteins. According to the researchers, this small, yet highly-potent drug-like molecule, currently in lab-testing, is being used to understand how different breast cancer cells might be susceptible to having RNA splicing interrupted. The drug molecule interferes with the molecular machinery that stiches gene sequences together to make fully functional proteins. Mutations in RNA splicing genes and defects in splicing have been found in diverse cancers, including breast cancer. The prototype drug molecules are allowing Dr. Aparicio and his team to seek out situations where cancer cells are uniquely susceptible to interference with RNA splicing. As alluded to, both drug development studies are currently centered in breast cancer treatment, but hope to expand to other types, including prostate and ovarian. Dr. Aparicio and his team’s work was supported with strategic funding from the BC Cancer Foundation. In Business new, two European firms are teaming up with Vancouver based regenerative medicine company, RepliCel Life Sciences Inc.to assist RepliCel in getting its commercial-grade RCI-02 dermal injector prototypes manufactured and tested. One of the partnering firms, AMI, is an Austrian manufacturer of medical technology based near the shores of Lake Constance, within easy reach of Germany and Switzerland. AMI develops, manufactures and distributes their medical products throughout the world. All of them are made according to the highest quality standards and enable doctors to take even better care of their patients. The second partner, Art of Technology (AoT), is based in Zurich Switzerland and is an independent contract developer specializing in the design, development and miniaturization of complex customer specific electronic devices and embedded systems for use in industrial, medical and space applications. The RCI-02 injector itself was designed with input from dermatologists, industrial designers, and electronic and medical device engineers to improve the delivery of a variety of injectables in a controlled, precise manner, removing the risks and uncertainties of injection outcomes currently resulting from manually operated, single-needle syringes. According to RepliCel president and CEO, Lee Buckler, it is the world’s first motorized injection device with programmable depth and volume, a built-in Peltier element for pre-injection anaesthetising, and interchangeable needle head configurations. It is designed to deliver a variety of injectable substances including cells, dermal fillers, drugs or biologics intradermally (dermis), subcutaneously (fat) or intramuscularly (muscle) via an array of needle configurations ranging from a single needle to a 16 needle configuration (4×4) on one head. Buckler adds that the execution of these agreements covers what RepliCel believes to be the final stages needed to prepare RCI-02 for a market authorization application in the form of a CE mark in Europe. The company hopes to have the device ready for a CE mark application and in the hands of a licensing and commercial partner next year. Our next story takes us to the Maritime provinces where the Terry Fox Research Institute is investing $5-million in support of New Brunswick researchers and their colleagues at other cancer centres in Canada to study how new precision medicine tools could improve, and potentially save the lives of patients diagnosed with the incurable cancer of the blood and bone marrow, known as multiple myeloma. The initiative is known as the Multiple Myeloma Molecular Monitoring (M4) Study, and Dr. Tony Reiman, a medical oncologist and professor at the University of New Brunswick, will lead the team, which comprises researchers and clinicians at multiple sites including Vancouver, Calgary, Toronto and Montreal. Dr. Reiman says that he hopes the five-year study will result in game-changing new approaches to identifying, treating and monitoring the disease in patients, including those who are at high risk of relapse. His team in Saint John will organize all the participating centres as well as conduct its own research and receive and bank specimens (blood and marrow) from the 250 myeloma patients that will participate in the project. Additionally, M4 study team members will use tests based on advanced techniques like immunoglobulin gene sequencing, multiparameter flow cytometry, PET scans, circulating tumour DNA analysis, and novel drug resistance assays to evaluate the patient specimens and other biosamples. Principal investigators at the partner sites are: Drs. Donna Reece and Suzanne Trudel, Princess Margaret Cancer Centre; Dr. Nizar Bahlis, University of Calgary; and Dr. François Bénard, BC Cancer Agency. Patients will be recruited by the study investigators at their own sites. Principal investigators Drs. Reece and Trudel (PM) explain their role in M4 study in the following audio. BrainStorm Cell Therapeutics Inc., a HACKENSACK, N.J.- based company developing adult stem cell technologies for neurodegenerative diseases, has signed an agreement with CCRM in the hopes of furthering its market authorization request for NurOwn®.  For our new listeners, CCRM is a Toronto-based company focused on developing and commercializing regenerative medicine technologies, specifically cell and gene therapies. Through the agreement, CCRM will help Brainstorm explore opportunities to access Health Canada’s early access pathway for treatment of patients with Amyotrophic Lateral Sclerosis (ALS).  If NurOwn® qualifies for Health Canada’s “Notice of Compliance with Conditions” pathway, it could be authorized in Canada for distribution in early 2018. Through the agreement, the company will work Patrick Bedford, manager of clinical translation and regulatory affairs at CCRM. Stacey Johnson (@msstaceyerin) , director, communications and marketing at CCRM and editor of Signals Blog discussed this deal recently via her regular Right Turn column Be sure to check it out at http://www.signalsblog.ca/right-turn-new-stem-cell-product-for-als-seeking-approval-in-canada/. For our final story, nearly a year since it’s failed KIACTA™ Phase 3 trial and subsequently being forced into pulling the plug on its KIACTA program, BELLUS Health is back from the brink as the Montreal-based company announced a new partnership and licensing deal with The NEOMED Institute to take over the development and commercialization activities for a potential new treatment for chronic cough. According to Bellus stakeholders,, this is a transformative transaction as this exclusive worldwide license agreement adds to the company’s pipeline a potentially best-in-class drug candidate, BLU-5937, an asset which was formerly known as NEO5937.  Its development through  the P2X3 antagonist program was initiated by AstraZeneca scientists in Montreal, and assigned to NEOMED in October 2012 when the NEOMED Institute was first launched. It was selected as a drug candidate to advance towards the clinic based on development efforts and extensive pre-clinical work in chronic cough done at NEOMED. According to Roberto Bellini, president and CEO of the company, the drug now going by its new name BLU-5937  will be a core focus of BELLUS’s drug development efforts. About the condition, Chronic cough is a cough that lasts eight weeks or longer and significantly impacts quality of life, with significant social (exclusion, embarrassment, difficulty speaking), physical (sleep deprivation, rib fracture, vomiting) and psychosocial (anxiety, depression) repercussions. It is estimated that in the U.S. alone, more than 2.7 million patients suffer from chronic cough that is not controlled by currently available medications. How BLU-5937 works to treat it, is it acts on a clinically validated target in the chronic cough pathway, the P2X3 receptor. Both the company and NEOMED believe BLU-5937 has the potential to become a best-in-class treatment option because of its superior potency and selectivity for the P2X3 receptor. These properties suggest BLU-5937 will be effective and less likely to cause a problematic side effect seen with less-selective drugs: taste disturbances that are significant enough to affect drug compliance. Under the terms of the agreement, BELLUS Health will pay NEOMED an upfront fee of $3.2 million, consisting of $1.7 million in cash with $1.5 million worth of BELLUS Health common shares (Approximately 5,802,177 shares). NEOMED will also be entitled to receive a royalty on net sales-based revenues. Additionally, in lieu of milestone payments, a certain portion of all other revenues received by BELLUS Health from BLU-5937 will be shared with NEOMED according to a pre-established schedule whereby the shared revenue portion decreases as the program progresses in development. Well that wraps up another episode of the Biotechnology Focus Podcast. We hope you enjoyed it. Be sure to let us know what you think, and we’re also always looking for story ideas and suggestions for future shows, and of course we’d love to hear from you as well, simply reach out to us via twitter @biotechfocus, or by email at the following email address  press@promotivemedia.ca. And remember, you can also listen to past episodes online via our podcast portal at www.biotechnologyfocus.ca . For all of us here at Biotechnology Focus, thanks for listening

Episode 169: Molecular physiologist Chad Macias, of the Institute for Human Kinetics, discusses some limitations of research, issues of misinterpretation and/or inaccurate communication related to research on cancer, nutritional ketosis and the press-pulse method. Chad is currently pursuing post-graduate research in Molecular Oncology. Chad has spent over 19 years conducting research and developing protocols in cellular and molecular physiology. He is an adjunct faculty member at the University of San Diego, and has developed some of the most advanced blood lactate testing and intermittent hypoxia protocols in the world. He founded the Institute for Human Kinetics in 2011, where he works with many of the world’s top athletes. In addition, he was a two sport Olympic athlete. He also serves as the Human Performance Specialist at Navy Special Warfare developing programs to prepare Navy Seals for combat deployment though their Tactical Athlete Program. Chad also heads OPI’s Research Team and has the knowledge base to conduct medical and exercise physiology research in both humans and rodents.

Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an "umbrella protocol" in which all patients undergo molecular testing and have treatment assigned by the results.

Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an "umbrella protocol" in which all patients undergo molecular testing and have treatment assigned by the results.

Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an "umbrella protocol" in which all patients undergo molecular testing and have treatment assigned by the results.

It's no secret that America's molecular testing laboratories by and large are worried that the FDA's plan to regulate laboratory developed tests, or LDTs, will severely harm patients. Now they have a new proposal which they are taking directly to Capitol Hill. Roger Klein is the Medical Director of Molecular Oncology at the Cleveland Clinic. He’s also serving as the spokesperson for the Association for Molecular Pathology (AMP) on the controversial topic of regulating LDTs.

Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.

Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.

Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.

Dr. Lecia Sequist of Massachusetts General Hospital, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.

Dr. Lecia Sequist of Massachusetts General Hospital, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.

Dr. Lecia Sequist of Massachusetts General Hospital, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.

Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.

Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.

Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.

Dr. Geoffrey Oxnard conveys a central theme that the benefits of molecular oncology and optimal application of targeted therapies are dependent on a change in collecting tissue that works to obtain far more tissue than was historically required.

Dr. Geoffrey Oxnard conveys a central theme that the benefits of molecular oncology and optimal application of targeted therapies are dependent on a change in collecting tissue that works to obtain far more tissue than was historically required.

Dr. Geoffrey Oxnard conveys a central theme that the benefits of molecular oncology and optimal application of targeted therapies are dependent on a change in collecting tissue that works to obtain far more tissue than was historically required.

Thomas Vaccari, IFOM - FIRC Institute of Molecular Oncology, Milan, ITALY speaks on "Trafficking and signaling: complementary characters in tumor suppression".This seminar has been recorded by ICGEB Trieste

Elisabetta Dejana, IFOM, FIRC Institute of Molecular Oncology, Milan, ITALY, speaks on "Molecular mechanisms of vascular remodelling and their alterations in human vascular pathologies". This seminar has been recorded by ICGEB Trieste

Elisabetta Dejana, IFOM, FIRC Institute of Molecular Oncology, Milan, ITALY, speaks on "Molecular mechanisms of vascular remodelling and their alterations in human vascular pathologies". This seminar has been recorded by ICGEB Trieste

Tian Xu, Yale Professor of Genetics, Molecular Oncology and Development; Vice-Chair, Department of Genetic, delivers a lecture concerning the next state of the human genome at the Yale Tomorrow campaign launch.